The impact of JAK2 V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70198 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Ryan Brown und 13 weiteren Autor:innen. Beteiligte Einrichtung: Regional Molecular Diagnostic Service, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK. Hauptthemen laut MEDLINE: Janus Kinase 2, Interferon-alpha, Polyethylene Glycols, Myeloproliferative Disorders. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Treatment with pegylated interferon α resulted in a molecular response in 91% of patients with an average decrease in JAK2V61F VAF of 48.5% from baseline. In patients that discontinued treatment, the JAK2V617F VAF at the time of treatment discontinuation was the best indicator of durable remission over the 6-month follow-up period. Created with SMART Servier Medical Art (https://smart.servier.com/).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Molecular Diagnostic Service, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
- School of Biological Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK.
- Haematology Department, Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.
- Haematology Department, Northern Health and Social Care Trust, Antrim, Northern Ireland, UK.
- Haematology Department, Southern Health and Social Care Trust, Craigavon, Northern Ireland, UK.
- Centre for Medical Education, Queens University Belfast, Belfast, Northern Ireland, UK.
ORCID-Profile: Ryan Brown
Zitieren
APA
Brown, R., Bennett, R., Crean, C., Hindley, A., McGimpsey, J., Cunningham, N., Niblock, A., McPherson, S., Boyd, K., Foy, A., Graham, C., Greenfield, G., McMullin, M. F., & Catherwood, M. A. (2025). The impact of JAK2 V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation. British Journal of Haematology. https://doi.org/10.1111/bjh.70198
Vancouver
Brown R, Bennett R, Crean C, Hindley A, McGimpsey J, Cunningham N, et al. The impact of JAK2 V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation. British Journal of Haematology. 2025. doi:10.1111/bjh.70198
BibTeX
@article{Brown2025,
author = {Brown, Ryan and Bennett, Rebekah and Crean, Clare and Hindley, Andrew and McGimpsey, Julie and Cunningham, Nicholas and Niblock, Aaron and McPherson, Suzanne and Boyd, Kathryn and Foy, Allister and Graham, Ciaren and Greenfield, Graeme and McMullin, Mary Frances and Catherwood, Mark A},
title = {The impact of JAK2 V617F variant allele frequency in MPN patients following PEGylated interferon alpha discontinuation},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70198}
}
EUVIMED